Fatty liver disease

BioAdaptives Announces the Development of VeganHepPlusTM Liver Supplement Formula

Retrieved on: 
Thursday, November 16, 2023

LAS VEGAS, NV, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, highlights the importance of liver support as experts predict a steady rise of the most common form of chronic liver disease over the next 25 years.

Key Points: 
  • Scientists presenting at The Liver Meeting , held by the American Association for the Study of Liver Diseases this week, predict nearly twice as many liver cancers and almost triple the need for liver transplantation by 2050.
  • Researchers also focused on increases in air pollution and the impact this will have on liver disease.
  • To help support healthy liver function, BioAdaptives has announced the development of VeganHepPlusTM, a novel, all-natural, vegan supplement formula designed to promote liver detoxification and support healthy hepatic function.
  • Edward Jacobs, M.D., CEO at BioAdaptives, stated, “We are very pleased to announce the development of VeganHepPlusTM, part of BioAdaptives’ strategic offering of products designed to address a wider spectrum of common health issues.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, November 15, 2023

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The equity awards were granted as an inducement material to the employees’ acceptance of employment with the company.
  • All awards described under (1) and (2) above shall be subject to each such employee’s continued employment as of the vesting date.
  • The exercise price per share for the stock options described above is $146.00.

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, November 14, 2023

FOSTER CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today reported financial results for the quarter ended September 30, 2023 and provided corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $14.8 million for the quarter ended September 30, 2023, as compared with $12.2 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $18.4 million for the quarter ended September 30, 2023, as compared with $5.1 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $29.8 million for the quarter ended September 30, 2023, as compared with $16.8 million for the quarter ended September 30, 2022.

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023

FOSTER CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced the late-breaking oral presentation of top-line data from its Phase 2a DUET clinical trial of TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist for the treatment of NASH. TERN-501 was evaluated alone and in combination with the Company’s liver-distributed farnesoid X receptor (FXR) agonist TERN-101. These data will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), on Monday, November 13 at 2:00 p.m. ET in Boston, Massachusetts.

Key Points: 
  • TERN-501 was evaluated alone and in combination with the Company’s liver-distributed farnesoid X receptor (FXR) agonist TERN-101.
  • These data will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), on Monday, November 13 at 2:00 p.m.
  • “These top-line data of TERN-501 are encouraging, with significant reductions in key biomarkers including liver fat content, MRI-PDFF, and cT1, a marker of fibro-inflammation.
  • Terns will host an investor reception event during The Liver Meeting in Boston on Monday, November 13 at 4:00 p.m.

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

Retrieved on: 
Monday, November 13, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today shared positive, comprehensive results from its Phase 2b ALPINE 4 trial of aldafermin, an engineered FGF19 analog product candidate, in patients with compensated cirrhosis (liver fibrosis stage 4 or F4) due to NASH in an oral plenary presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.

Key Points: 
  • The ALPINE 4 data shared at AASLD The Liver Meeting follow positive topline results on the primary endpoint reported by NGM Bio in May 2023.
  • It’s gratifying to see the potential impact aldafermin is having on NASH progression and liver health in patients with F4 NASH.
  • This Phase 2b data set furthers our belief in aldafermin’s therapeutic potential,” said Hsiao D. Lieu, M.D., Chief Medical Officer at NGM Bio.
  • ELF measures direct markers of liver fibrosis and can be used to predict liver-related events in patients with NASH and compensated cirrhosis.

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

Retrieved on: 
Friday, November 10, 2023

Hepion is pleased to invite all interested parties to participate in a conference call at 4:30 p.m.

Key Points: 
  • Hepion is pleased to invite all interested parties to participate in a conference call at 4:30 p.m.
  • ET on November 13, 2023, during which the additional ALTITUDE-NASH efficacy data will be discussed.
  • To participate in this conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international), conference ID 8619177, approximately 10 minutes prior to the start time.
  • The call will also be broadcast live and archived on the Company’s website at www.hepionpharma.com under “Events” in the Investors section.

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023

SAN MATEO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced the presentation of preclinical results detailing artificial intelligence (AI) based digital pathology of Sagimet’s FASN inhibitor alone or in combination with semaglutide in a preclinical mouse model of nonalcoholic steatohepatitis (NASH). A comprehensive lipidomic analysis from the interim analysis of the FASCINATE-2 Phase 2b clinical trial will also be presented in a late-breaking poster session at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023 held November 10-14, 2023 in Boston.

Key Points: 
  • A single treatment of a FASN inhibitor or semaglutide - improved the NAFLD activity score, or NAS, (NAS ≥ 1 point, 47% and 56%, respectively).
  • The combination of a FASN inhibitor and semaglutide showed further improvement of NAS (94%, p
  • Semaglutide reduced body weight by >20% in NASH mice, alone, or in combination with a FASN inhibitor.
  • The digital AI pathology assessment showed that treatment with a FASN inhibitor alone, or in combination with semaglutide significantly reduced liver fibrosis (p

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

Retrieved on: 
Friday, November 10, 2023

Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.

Key Points: 
  • Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.
  • It is the only investigational therapy for NASH that has achieved both fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial.
  • Resmetirom also reduced levels of LDL cholesterol and other lipids that are associated with heart disease.
  • Resmetirom is an investigational therapy and has not been approved by the FDA or any other regulatory authority.

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

Retrieved on: 
Friday, November 10, 2023

CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer.

Key Points: 
  • CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer.
  • This included executing the launch of Dupixent, a first-in-class therapy which has grown into an industry-leading medicine.
  • In 2022, Ms. Huntsman’s business unit was responsible for over $10 billion in annual net sales.
  • Bill Sibold, Chief Executive Officer of Madrigal, stated, “Carole Huntsman’s leadership skills and experience are a perfect fit for Madrigal as we prepare for a first-to-market launch of resmetirom in the U.S. She has an extensive track record of specialty launch success and excels in building and leading high-performing teams that deliver innovative new therapies to patients with serious diseases.

Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13

Retrieved on: 
Thursday, November 30, 2023

Inipharm , a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today announced that it has begun dosing in a Phase 1 study of INI-822, its orally-delivered small molecule inhibitor of HSD17B13.

Key Points: 
  • Inipharm , a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today announced that it has begun dosing in a Phase 1 study of INI-822, its orally-delivered small molecule inhibitor of HSD17B13.
  • INI-822, believed to be the first small molecule inhibitor of HSD17B13 to advance to clinical development, is under development for fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).
  • “I want to applaud the Inipharm team who has worked tirelessly to develop a small molecule that can inhibit HSD17B13,” said Brian Farmer, co-founder and chief executive officer of Inipharm.
  • “This target presents significant challenges with respect to the development of a small molecule inhibitor.